Featured
Jobs go as pharma restructure hits Australia
While the exact number of roles or business functions impacted has not been officially disclosed, it’s understood redundancies have hit the commercial team
Pipeline & Intellectual Property
CSL makes $1.7B bet on first-in-class hopeful
Exclusive global partnership to co-develop and co-promote a potential game-changing therapy across a range of kidney and liver diseases
Regulatory & Reimbursement
Aussie first hits lucrative market
Roche is delivering the first innovative solution of its kind to Australian patients with the company already heading to the PBAC for reimbursement
Regulatory & Reimbursement
Fourth sponsor enters hot biosimilar market
A new competitor to what was once the top-selling drug on the PBS plus approval for the first generic of a drug first registered in Australia in 1991
Regulatory & Reimbursement
First rival but no price cut for $20M drug
Even though three 'first new brands' shouldered onto the PBS at the start of October in competition with this $20M drug, there's been no price haircut
Regulatory & Reimbursement
Longer US life... but what about Australia?
An Australian-developed drug forecast to earn half a billion this year just got another five years of patent protection in the US but plans for Australian registration are still missing
Industry & Companies
Number of Best Workplaces in Aussie Pharma doubles
Now in its third year, the industry-specific list, compiled by Great Places to Work has doubled in size, with 10 companies making the cut in 2026
Pipeline & Intellectual Property
Has Lilly moved the goal posts in weight loss?
Impressive new trial results may have changed what weight loss drugs need to achieve to grab a slice of the market
Jobs & Workplace
Novartis General Manager departs
Well-known GM for New Zealand says he's looking forward to spending time with family, recharging, and exploring what's next
Regulatory & Reimbursement
First rival triggers price cut for $70M drug
Biosimilar maker picks up three reimbursements for October, one of which triggered a statutory 25 per cent price cut for a $70M-a-year drug
Regulatory & Reimbursement
October listing a win for complex condition
A treatment that provides a much-needed alternative option for people with atopic dermatitis has hit the PBS
Regulatory & Reimbursement
Govt trumpets groundbreaking cancer results
An 86 per cent complete response rate from a study that combined three drugs sponsored by AbbVie, BMS, and Roche has been shared by a State Government as part of its election commitment
Regulation & Legal
Info sheet breaches Aussie Code
Materials informing HCPs of a change to PBS criteria were worded in a way that breached the Code of Conduct, an MA Committee has determined
Pipeline & Intellectual Property
AZ buys in before Summit's peak?
In what could be a savvy move, AZ has acquired more than 10 per cent of Summit Therapeutics ahead of much-hyped trial results
Featured
Drug approvals slide in Australia
After a mammoth year of prescription drug approvals in 2025, the registration of both new drugs and new indications for existing medicines fizzles
Jobs
Featured
Who's Australia's Most Trusted (and Distrusted) pharma?
When it comes to trust and distrust two pharmas stand out, Australian research has found. See who's on a winning streak
Industry & Companies
Patients pick ANZ's best pharma
The pharma with industry's best Corporate Reputation jumped five places to take the top spot, thanks to an overwhelming response from patients who had worked with the company
Industry & Companies
Women in pharma hit milestone
Ahead of its much-anticipated end-of-year event next month, this fledgling Australian branch of a global networking group has already passed a major milestone
Industry & Companies
Biogen staff spread early Christmas cheer
The volunteering experience provided employees with a first-hand understanding of the scale of community need and the importance of supporting vulnerable Australians
Jobs & Workplace
Tax reform could force Aussie jobs overseas
Peak body for life sciences professionals warns a raft of Aussie pharma roles could move overseas if certain changes to the R&D Tax Incentive go through
Regulation & Legal
TGA goes to court over prescription meds
Australia’s medicines regulator has commenced proceedings in the Federal Court, alleging unlawful advertising of prescription-only medicines
Regulatory & Reimbursement
Time to use the C-word for multiple myeloma?
After analysing trial results which produced astounding results J&J is optimistic for a future where MM is no longer defined as incurable
Sales, Marketing & Public Relations
TV star speaks out for GSK campaign
At a high-profile campaign launch in the heart of Sydney's CBD, a much-loved celebrity revealed the impact this disease has had on her life and that of her family
Regulatory & Reimbursement
PBAC unpacks pet peeves about pharma
Lifting the lid on the frustrating mismatch between what the Committee says it needs in order to make a recommendation and what sponsors dish up
Sales, Marketing & Public Relations
New tool puts KOLs on pharma's radar
Finding and validating KOLs across therapeutic areas just got a lot easier with a new AI-powered tool that does the heavy lifting for Medical Affairs teams
Industry & Companies
Trump nabs secret slice of Aussie drug prices
Documents obtained under Freedom of Information, suggest the US Government will share in the increased revenue pharmas generate by lifting drug prices outside the US
Sales, Marketing & Public Relations
Lilly hit by health industry backlash
Platform sparks outrage from pharmacists and doctors claiming the 'Americanisation' of Australian healthcare, an accusation the company vehemently denies
- Regulatory & Reimbursement First new drug in almost 20 years launched
- Industry & Companies Missing data sinks Aussie Phase 3 trial
- Regulatory & Reimbursement Hyped drug approved after 5-plus years
- Regulatory & Reimbursement Takeda snaps up recently vacated market
- Industry & Companies New office brings pharma team together
- Industry & Companies MA board voting opens: three leaders, two seats
- Industry & Companies Pharma downsizes in Australia
- Industry & Companies Aussie staff let go as pharma put up for sale
- Leadership & People Who made Australia's Most Powerful People list?
- Regulatory & Reimbursement Changed global pricing sinks PBS listing
